Humanized anti-axl antibodies

Abstract

The present disclosure relates to humanized anti-Axl antibodies.

1 .- 31 . (canceled) 
     
     
         32 . An isolated humanized antibody that binds to AXL, wherein the isolated humanized antibody comprises:
 a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3; and   a light chain variable region having the amino acid sequence of SEQ ID NO: 4, 5, 6, 7, or 8.   
     
     
         33 . The isolated humanized antibody according to  claim 32 , wherein the isolated humanized antibody comprises:
 (i) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region having the amino acid sequence of SEQ ID NO: 4;   (ii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region having the amino acid sequence of SEQ ID NO: 5;   (iii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region having the amino acid sequence of SEQ ID NO: 6;   (iv) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region having the amino acid sequence of SEQ ID NO: 7;   (v) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2 and a light chain variable region having the amino acid sequence of SEQ ID NO: 8;   (vi) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region having the amino acid sequence of SEQ ID NO: 4;   (vii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region having the amino acid sequence of SEQ ID NO: 5;   (viii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region having the amino acid sequence of SEQ ID NO: 6;   (viv) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region having the amino acid sequence of SEQ ID NO: 7; or   (x) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 3 and a light chain variable region having the amino acid sequence of SEQ ID NO: 8.   
     
     
         34 . The humanized antibody according to  claim 32 , wherein said antibody or antibody fragment has a constant region of isotype IgG1, IgG2, IgG3 or IgG4, or a mutated IgG constant region. 
     
     
         35 . The humanized antibody according to  claim 32 , wherein said antibody or antibody fragment has a light chain constant region of isotype kappa or lambda. 
     
     
         36 . The humanized antibody according to  claim 32 , wherein the humanized antibody fragment is a scFv, Fab or F(ab) 2 . 
     
     
         37 . A method of treating a proliferative disease in a subject, comprising administering to the subject an antibody according to  claim 32 . 
     
     
         38 . A polynucleotide encoding a humanized antibody according to  claim 32 . 
     
     
         39 . A vector comprising the polynucleotide of  claim 38 . 
     
     
         40 . The vector of  claim 39  wherein the vector is an expression vector. 
     
     
         41 . A host cell comprising a vector according to  claim 39 . 
     
     
         42 . The host cell according to  claim 41  wherein the host cell is prokaryotic, eukaryotic, or mammalian. 
     
     
         43 . A method of making a humanized antibody that binds to AXL, the method comprising culturing the host cell according to  claim 41  under conditions for production of said antibody. 
     
     
         44 . The method according to  claim 43 , further comprising isolating said antibody. 
     
     
         45 . The method according to  claim 44 , further comprising formulating the antibody into a composition including at least one additional component.